Andres Forero-Torres
Hematology & Oncology · Birmingham, ALNPI 1265476352
Payments from drug & device makers
What this record shows
This record is dominated by education: $12 of the $12 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, Epizyme, Inc.. That places this record below the midpoint for hematology & oncology clinicians in AL, where the typical reported total is $7,159.
Across 1 payment — averaging $11.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Epizyme, Inc.$12
Across 33 payments — averaging $26,360 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$410K
- Tesaro, Inc.$162K
- Seagen Inc.$161K
- Pfizer$85K
- Incyte Corporation$43K
- AstraZeneca$4K
- plus $5K from 2 others
What the payments were for
- Education$12100%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Epizyme, Inc. | 1 | $12 |
How this compares
$12 in reported general payments places this provider in the 0th percentile of 177 hematology & oncology providers in Alabama.
Other hematology & oncology in Birmingham
- Amitkumar MehtaBirmingham$683K
- Pankit VachhaniBirmingham$545K
- Luciano CostaBirmingham$409K
- Khaleel AshrafBirmingham$379K
- Michael BirrerBirmingham$302K
- Rudolph NavariBirmingham$254K
- Mayur NarkhedeBirmingham$193K
- Midhun MallaBirmingham$144K
- Robert ConryBirmingham$143K
- David MooneyBirmingham$120K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.